Screening drug effects in patient‐derived cancer cells links organoid ...

Screening drug effects in patient-derived cancer cells links organoid ...

Cancer drug screening in patient-derived cells holds great promise for personalized oncology and drug discovery but lacks standardization.

DeathPro resolves cytotoxic and cytostatic effects in drug screens with patient‐derived ovarian and lung cancer cells, organoids and co‐cultures with ...

Screening drug effects in patient‐derived cancer cells links organoid ...

Figure EV1. DeathPro assay resolves drug responses in ovarian cancer co‐cultures, xenograft‐derived cells and lung cancer organoids. ... By using ...

Resolving drug effects in patient-derived cancer cells links organoid ...

Using DeathPro, we screened cells from ovarian cancer patients in monolayer or organoid culture with clinically relevant drugs. Drug-induced ...

Screening drug effects in patient‐derived cancer cells links organoid ...

Article ; Screening drug effects in patient-derived cancer. cells links organoid responses to genome alterations ; Julia Jabs. 1,2,3 ;, Franziska ...

Patient-derived organoids as a platform for drug screening in ...

Historically, cancer cell lines and patient-derived tumor xenografts (PDTXs) have been used as preclinical models to assess the clinical ...

Personalized drug screening using patient-derived organoid and its ...

We successfully established 57 organoids derived from these GC tumor tissues with an overall success rate of 78% (57/73) (Figure 1A).

Patient-derived organoid (PDO) platforms to facilitate clinical ...

Showing numerous advantages over 2D cell lines, 3D cell lines, and primary cell culture, organoids have been applied in drug screening to ...

Patient-derived organoids as a predictive biomarker for treatment ...

Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, ...

Patient-Derived Organoids in Precision Medicine: Drug Screening ...

The intratumor diversity in PDOs captures tumor heterogeneity at the single cell level and provides a valuable resource for cancer research. PDO ...

Drug-repurposing screen on patient-derived organoids identifies ...

Screening drug effects in patient-derived cancer cells links organoid re- sponses to genome alterations. Mol. Syst. Biol. 13, 955. https ...

Patient‐derived cancer organoids for drug screening: Basic ...

Tumor organoids could identify the direct effects of chemotherapy on cancer cells. So far, some patient-derived organoids have been used to ...

A simple high-throughput approach identifies actionable drug ...

Tumor organoids maintain cell–cell interactions, heterogeneity, microenvironment, and drug response of the sample they originate from.

Drug screening model meets cancer organoid technology

Many studies had shown that organoids were superior to 2D cell lines and PDX in terms of stability and fidelity as a drug screening model [24,25]. However, due ...

Application of Cancer Organoid Model for Drug Screening and ...

Drug screening—i.e., testing the effects of a number of drugs in multiple cell lines—is used for drug discovery and development, and can also be performed ...

Patient-derived organoids in human cancer: a platform for ...

They have been efficaciously implemented in illness portrayal, mechanism exploration, high-throughput drug screening and assessment, discovery ...

Personalized drug screening in patient-derived organoids of biliary ...

In conclusion, BTC PDO is a promising precision medicine tool for anti-cancer therapy in BTC patients. INTRODUCTION. Biliary tract cancer (BTC) ...

Resolving drug effects in patient-derived cancer cells links organoid ...

Cancer drug screening in patient-derived cells holds great promise for personalized oncology and drug discovery but lacks standardization. Whether cells are ...

Patient‐derived cancer organoids for drug screening

Different from cancer cell lines and PDTX, cancer organoids are three-dimensional (3D) aggregates differentiated from pluripotent stem cells or isolated organ ...

Clinical translation of patient-derived tumour organoids- bottlenecks ...

The reported time for a drug screen on gastric cancer organoids is less than 2 weeks [41], but this is largely dependent on the number of drugs ...